Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases
Pathobiology · 2024
DOI: 10.1159/000535938 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pathobiology, 2024. Verfasst von Vanesa-Sindi Ivanova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland, vanesa-sindiivelinova.iva…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, In Situ Hybridization, Fluorescence, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity. Lately, several algorithms achieving therapeutically and prognostically relevant DLBCL subclassification have been published.
Methods
A cohort of 74 routine DLBCL cases was broadly characterized by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) of the BCL2, BCL6, and MYC loci, and comprehensive high-throughput sequencing (HTS). Based on the genetic alterations found, cases were reclassified using two probabilistic tools – LymphGen and Two-step classifier, allowing for comparison of the two models.
Results
Hans and Tally’s overall IHC-based subclassification success rate was 96% and 82%, respectively. HTS and FISH data allowed the LymphGen algorithm to successfully classify 11/55 cases (1 – BN2, 7 – EZB, 1 – MCD, and 2 – genetically composite EZB/N1). The total subclassification rate was 20%. On the other hand, the Two-step classifier categorized 36/55 cases, with 65.5% success (9 – BN2, 12 – EZB, 9 – MCD, 2 – N1, and 4 – ST2). Clinical correlations highlighted MCD as an aggressive subtype associated with higher relapse and mortality.
Conclusions
The Two-step algorithm has a better success rate at subclassifying DLBCL cases based on genetic differences. Further improvement of the classifiers is required to increase the number of classifiable cases and thus prove their applicability in routine diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland, vanesa-sindiivelinova.ivanova@usb.ch.
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Oncology, Hôpital du Jura, Delemont, Switzerland.
- Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
- Onkologie Dreilaendereck, Loerrach, Germany.
Zitieren
APA
Ivanova, V. S., Vela, V., Dirnhofer, S., Dobbie, M., Stenner, F., Knoblich, J., Tzankov, A., & Menter, T. (2024). Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases. Pathobiology. https://doi.org/10.1159/000535938
Vancouver
Ivanova VS, Vela V, Dirnhofer S, Dobbie M, Stenner F, Knoblich J, et al. Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases. Pathobiology. 2024. doi:10.1159/000535938
BibTeX
@article{Ivanova2024,
author = {Ivanova, Vanesa-Sindi and Vela, Visar and Dirnhofer, Stefan and Dobbie, Michael and Stenner, Frank and Knoblich, Jan and Tzankov, Alexandar and Menter, Thomas},
title = {Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases},
journal = {Pathobiology},
year = {2024},
doi = {10.1159/000535938}
}
EUVIMED